Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Seon-Ok Kim"

Article category

Keywords

Publication year

"Seon-Ok Kim"

Original Articles
Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein
Dongman Yu, Yeongseok Hwang, Jin-Sung Ju, Subin Heo, Seon-Ok Kim, Sang Hyun Choi, Gi-Won Song, Jihyun An, Ju Hyun Shim
Clin Mol Hepatol 2026;32(2):751-771.
Published online January 9, 2026
DOI: https://doi.org/10.3350/cmh.2025.0986
Background/Aims
Various expanded criteria (EC) for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) have been proposed to avoid the narrow nature of the Milan criteria (MC). To investigate which EC predicts more favorable outcomes in terms of overall survival (OS) and recurrence-free survival (RFS), we conducted a network meta-analysis (NMA).
Methods
A database search was conducted on PubMed, Embase, and the Cochrane Library, to identify studies comparing OS and RFS between patients within the MC and those exceeding the MC but within the EC. Hazard ratios (HRs) were pooled using a random-effects NMA and validated in an in-house cohort of 1,008 LT recipients.
Results
Among 22,466 articles identified, 35 studies with 45 pairwise comparisons were included in the NMA along with 8 different EC. The University of California San Francisco (HR, 1.43; 95% CI, 1.19–1.71), Up-to-Seven (HR, 1.50; 95% CI, 1.15–1.97), and Hangzhou criteria (HR, 1.69; 95% CI, 1.11–2.57) showed inferior OS to the MC. The MC ranked highest for both OS and RFS, followed by Metroticket 2.0 for OS and the Asan criteria for RFS. In the validation cohort, both Metroticket 2.0 and AFP model yielded more favorable HCC-specific mortality than other EC.
Conclusions
Several EC, of which those of Metroticket 2.0 were the best, yielded comparable outcomes to the MC. AFP-based EC such as Metroticket 2.0 and AFP model appeared to be useful in both the NMA and the validation cohort, suggesting a potential role in identifying selected low-risk patients beyond the MC.

Citations

Citations to this article as recorded by  Crossref logo
  • Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review
    Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Claudio Basile, Giusy Senese, Annachiara Coppola, Patrizia Iodice, Simone Olivieri, Alessandro Federico, Marcello Dallio
    Journal of Clinical Medicine.2026; 15(10): 3579.     CrossRef
  • Shrinking Giants: On the Feasibility of Downsizing Hepatocellular Carcinoma with Immunotherapy Prior to Liver Transplantation
    Juraj Prejac, Domina Kekez, Hana Lučev, Borna Ćutić, Viktor Domislović, Vibor Šeša, Gordan Adžić, Marin Golčić
    Journal of Clinical Medicine.2026; 15(10): 3923.     CrossRef
  • Improving the choice of liver transplant for hepatocellular carcinoma: Editorial on “Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein”
    Jongman Kim
    Clinical and Molecular Hepatology.2026; 32(3): 1461.     CrossRef
  • From post-transplant outcomes to listing decisions: Clinical implications of comparing expanded hepatocellular carcinoma transplant criteria: Letter to the editor on “Network meta-analysis and validation study of expanded liver transplantation criteria fo
    Bo Ni, Hairui Wang
    Clinical and Molecular Hepatology.2026; 32(3): e315.     CrossRef
  • 2,650 View
  • 124 Download
  • 4 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Jihyun An, Hyung-Don Kim, Seon-Ok Kim, Ha Il Kim, Gi-Won Song, Han Chu Lee, Ju Hyun Shim
Clin Mol Hepatol 2022;28(1):67-76.
Published online October 12, 2021
DOI: https://doi.org/10.3350/cmh.2021.0202
Background/Aims
We aimed to investigate the silent atherosclerotic burden of cervicocephalic vessels in cirrhotic patients compared with the general population, as well as the relevant risk factors including coronary parameters.
Methods
This study included 993 stroke-free patients with liver cirrhosis (LC) who underwent magnetic resonance angiography (MRA) of the head and neck as a pre-liver transplant assessment and 6,099 health checkup participants who underwent MRA examination. The two cohorts were matched for cerebrovascular risk factors, and the prevalence of atherosclerosis in major intracranial and extracranial arteries was compared in 755 matched pairs. Moreover, traditional, hepatic, and coronary variables related to cerebral atherosclerosis were assessed in cirrhotic patients.
Results
Overall, intracranial atherosclerosis was significantly less prevalent in the LC group than in the matched control group (2.3% vs. 5.4%, P=0.002), whereas the prevalence of extracranial atherosclerosis was similar (4.4% vs. 5.8%, P=0.242). These results were maintained in multivariate analyses of the pooled samples, with corresponding adjusted odds ratios [ORs] of LC of 0.56 and 0.77 (95% confidence intervals [CIs], 0.36–0.88 and 0.55–1.09). In the LC group, lower platelet count was inversely correlated with intracranial atherosclerosis (adjusted OR, 0.31; 95% CI, 0.13–0.76). Coronary artery calcium (CAC) score ≥100 was the only predictive factor for both intracranial and extracranial atherosclerosis (adjusted ORs, 4.06 and 5.43, respectively).
Conclusions
LC confers protection against intracranial atherosclerosis, and thrombocytopenia may be involved in this protective effect. High CAC score could serve as a potential surrogate for cervicocerebral vascular screening in asymptomatic cirrhotic patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
    Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei
    Clinical and Molecular Hepatology.2022; 28(2): 265.     CrossRef
  • Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
    Jihyun An, Ju Hyun Shim
    Clinical and Molecular Hepatology.2022; 28(2): 267.     CrossRef
  • 9,750 View
  • 194 Download
  • 2 Web of Science
  • Crossref